|Bid||19.650 x 700|
|Ask||19.700 x 400|
|Day's Range||19.300 - 20.000|
|52 Week Range||11.850 - 21.010|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 30, 2018 - May 4, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.17|
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on January 31. Over the last one-month, outflows of investor capital in ETFs holding MNTA totaled $1.01 billion.
NEW YORK, March 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
CAMBRIDGE, Mass., March 05, 2018-- Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its ...
Stock Monitor: Momenta Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 27, 2018 / Active-Investors.com has just released a free earnings report on Catalent, Inc. (NYSE: CTLT ).If you ...
Momenta Pharmaceuticals Inc (NASDAQ:MNTA) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on January 31. Over the last one-month, outflows of investor capital in ETFs holding MNTA totaled $237 million.
Regeneron Pharmaceuticals (REGN) is a fully integrated biotechnology company with a focus on discovering, developing, manufacturing, and commercializing medicines for the treatment of eye diseases, allergic and inflammatory diseases, heart diseases, pain, cancer, and infectious medical conditions. Currently, the company has six key products on the market: Eylea injection, Dupixent injection, Praluent injection, Kevzara solution for subcutaneous injection, Arcalyst injection, and Zaltrap injection for intravenous infusion. Of the 27 analysts covering Regeneron Pharmaceuticals in February 2018, 12 of them have given the stock a “buy” or higher rating.
The Street has long been ambivalent on Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA )'s prospects. But the generic drug developer scored one new advocate Thursday on the basis of its pipeline potential. ...
NEW YORK, NY / ACCESSWIRE / February 22, 2018 / Shares of Nektar were soaring on Wednesday despite any catalyst. It was earlier in the month that the company announced a huge agreement with Bristol-Myers. ...
On a per-share basis, the Cambridge, Massachusetts-based company said it had profit of 18 cents. The biotechnology company posted revenue of $64.6 million in the period. For the year, the company reported ...
--Ended 2017 with a healthy cash position of $380 M--. --Recently announced FDA approval and launch of Glatopa ® 40 mg--. CAMBRIDGE, Mass., Feb. 21, 2018-- Momenta Pharmaceuticals, Inc. today reported ...
NEW YORK, NY / ACCESSWIRE / February 21, 2018 / Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 21, 2018 at 10:00 ...
This is the second generic Copaxone 40 mg/mL greenlighted by the U.S. Food and Drug Administration.
Moody's Investors Service says a second generic version of blockbuster multiple sclerosis drug, Copaxone, was approved today, a credit negative for Teva Pharmaceutical Industries Ltd ("Teva," ...